Payment overview · 2025
General Payments
$125.56
2 reported records · 2 companies
Healthcare provider profile · identity verified
Heather Straight, DO
Allopathic & Osteopathic Physicians|Family Medicine · SAINT MARYS, WV · NPI 1841292786
Verified facts
What the public records show
CMS Open Payments records show Heather Straight, DO received $125.56 in general payments during 2025 across 2 reported records.
Boston Scientific Corporation accounted for 88.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $111.29 | 88.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.27 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $111.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 817 | 248 |
| Levothyroxine Sodium | Levothyroxine Sodium | 668 | 176 |
| Lisinopril | Lisinopril | 649 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 138 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 436 | 126 |
| Sertraline Hcl | Sertraline Hcl | 401 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 116 |
| Omeprazole | Omeprazole | 369 | 117 |
| Gabapentin | Gabapentin | 343 | 55 |
| Losartan Potassium | Losartan Potassium | 324 | 104 |
| Metformin Hcl | Metformin Hcl | 318 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 86 |
| Potassium Chloride | Potassium Chloride | 267 | 73 |
| Trazodone Hcl | Trazodone Hcl | 251 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 78 |
| Fenofibrate | Fenofibrate Nanocrystallized | 212 | 62 |
| Montelukast Sodium | Montelukast Sodium | 211 | 62 |
| Ezetimibe | Ezetimibe | 192 | 73 |
| Buspirone Hcl | Buspirone Hcl | 187 | 48 |
| Furosemide | Furosemide | 187 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 58 |
| Meloxicam | Meloxicam | 169 | 56 |
| Allopurinol | Allopurinol | 163 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 43 |
| Simvastatin | Simvastatin | 149 | 48 |
| Alendronate Sodium | Alendronate Sodium | 144 | 47 |
| Metformin Hcl Er | Metformin Hcl | 137 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 132 | 37 |
| Ozempic | Semaglutide | 130 | 27 |
| Eliquis | Apixaban | 128 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 53 |
| Synthroid | Levothyroxine Sodium | 117 | 29 |
| Jardiance | Empagliflozin | 114 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 30 |
| Tramadol Hcl | Tramadol Hcl | 100 | 21 |
| Pregabalin | Pregabalin | 98 | 16 |
| Celecoxib | Celecoxib | 97 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 14 |
| Atenolol | Atenolol | 94 | 30 |
| Famotidine | Famotidine | 90 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 78 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 19 |
| Fenofibrate | Fenofibrate | 71 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 14 |
| Spironolactone | Spironolactone | 63 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 14 |
| Bupropion Xl | Bupropion Hcl | 59 | 17 |
| Glipizide | Glipizide | 58 | 16 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Lovastatin | Lovastatin | 56 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 16 |
| Carvedilol | Carvedilol | 53 | 18 |
| Farxiga | Dapagliflozin Propanediol | 52 | 16 |
| Finasteride | Finasteride | 52 | 13 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 15 |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Baclofen | Baclofen | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 17 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Alprazolam | Alprazolam | 45 | 13 |
| Sucralfate | Sucralfate | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 13 |
| Glimepiride | Glimepiride | 42 | 15 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 40 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 11 |
| Methocarbamol | Methocarbamol | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 16 |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Glyburide | Glyburide | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Nadolol | Nadolol | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.56 · 2 records | Boston Scientific Corporation | General - Vascular Intervention, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error